Compare ESTA & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESTA | TSHA |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2018 | 2020 |
| Metric | ESTA | TSHA |
|---|---|---|
| Price | $65.00 | $4.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $102.44 | $13.00 |
| AVG Volume (30 Days) | 278.2K | ★ 3.2M |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.67 | 5.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $61,208,000.00 | $9,773,000.00 |
| Revenue This Year | $28.00 | N/A |
| Revenue Next Year | $25.55 | $1,023.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 76.49 | 17.28 |
| 52 Week Low | $38.38 | $3.69 |
| 52 Week High | $97.59 | $7.30 |
| Indicator | ESTA | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 36.84 | 28.92 |
| Support Level | $64.11 | $4.37 |
| Resistance Level | $68.27 | $4.72 |
| Average True Range (ATR) | 2.42 | 0.26 |
| MACD | -0.19 | -0.02 |
| Stochastic Oscillator | 27.39 | 0.00 |
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.